Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose
Abstract We hypothesized that in individuals with previous SARS-CoV-2 infection, the first vaccine dose would work as a booster, eliciting a faster and more intense immune response. We herein describe antibody responses to the first and second doses of Gam-COVID-Vac (SPUTNIK V) vaccine in health personnel of Tucumán, Argentina, with previous COVID-19 and compared it with uninfected personnel. Individuals with anti-SARS-CoV-2 titers at baseline showed significantly higher responses to the first dose than people with no prior history of disease (p <0.0001), with titers higher to those registered after the second dose in the control group, representing a clear secondary antibody response. This suggests that a single dose of SPUTNIK V for people with previous SARS-CoV-2 infection could contribute to a better use of available doses. One-Sentence SummaryFirst vaccine dose in subjects with prior COVID19 elicits a higher antibody response than two doses in uninfected individuals
Mostoslavsky Gustavo、Chahla Rossana Elena、In¨|s Cazorla Silvia、Aznar Patricia、Alcorta Malena、del Mar V¨|lez Eva Mar¨aa、¨￠vila C¨|sar Lu¨as、Costas Dardo、Flores Isolina、Mostoslavsky Ra¨2l、Perdig¨?n Gabriela、Pingitore Esteban Vera、Navarro Silvia Adriana、Apfelbaum Gabriela、Ploper Diego、Stagnetto Agust¨an、Hern¨￠n Tomas-Grau Rodrigo、Llapur Conrado、Benjam¨an Socias Sergio、Maldonado-Galdeano Carolina、Cheh¨an Rosana Nieves、Heinze Dar、L¨?pez M¨?nica Aguilar
Section of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of MedicineTucum¨￠n Public Healthcare Administration (SIPROSA)Centro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nN¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)N¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)N¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)Instituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)N¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)N¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)The Massachusetts General Hospital Cancer Center, Harvard Medical SchoolCentro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)Instituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)School of Medicine ¨C Universidad Nacional de Tucum¨￠n. Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)Instituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)Instituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)N¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)Instituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)Centro de Referencia para Lactobacilos ¨C CERELA (CONICET). Tucum¨￠nInstituto de Medicina Molecular y Celular Aplicada - IMMCA (UNT-CONICET-SIPROSA)Section of Gastroenterology, Department of Medicine, Center for Regenerative Medicine (CReM), Boston University School of MedicineN¨|stor Kirchner Hospital, Central Public Health laboratory (LSP) (SIPROSA)
预防医学基础医学医学研究方法
Mostoslavsky Gustavo,Chahla Rossana Elena,In¨|s Cazorla Silvia,Aznar Patricia,Alcorta Malena,del Mar V¨|lez Eva Mar¨aa,¨￠vila C¨|sar Lu¨as,Costas Dardo,Flores Isolina,Mostoslavsky Ra¨2l,Perdig¨?n Gabriela,Pingitore Esteban Vera,Navarro Silvia Adriana,Apfelbaum Gabriela,Ploper Diego,Stagnetto Agust¨an,Hern¨￠n Tomas-Grau Rodrigo,Llapur Conrado,Benjam¨an Socias Sergio,Maldonado-Galdeano Carolina,Cheh¨an Rosana Nieves,Heinze Dar,L¨?pez M¨?nica Aguilar.Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose[EB/OL].(2025-03-28)[2025-05-22].https://www.medrxiv.org/content/10.1101/2021.03.14.21253039.点此复制
评论